References
- Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70(4), 767–777 (1972).
- Couch RB, Decker WK, Utama B et al. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS ONE 7(12), e50830 (2012).
- Cox RJ, Madhun AS, Hauge S et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27(13), 1889–1897 (2009).
- Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza a (H7N9) virus. N. Engl. J. Med. 368(20), 1888–1897 (2013).
- Xiong X, Martin SR, Haire LF et al. Receptor binding by an H7N9 influenza virus from humans. Nature 499(7459), 496–499 (2013).
- Watanabe T, Kiso M, Fukuyama S et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501(7468), 551–555 (2013).
- Ramos I, Krammer F, Hai R et al. H7N9 influenza viruses interact preferentially with α2,3-linked sialic acids and bind weakly to α2,6-linked sialic acids. J. Gen. Virol. doi:10.1099/vir.0.056184-0 (2013) ( Epub ahead of print).
- Hu Y, Lu S, Song Z et al. Association between adverse clinical outcome in human disease caused by novel influenza a H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381(9885), 2273–2279 (2013).
- Cox RJ, Major D, Hauge S et al. A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respi. Viruses 3(3), 107–117 (2009).
- Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr. Opin. Virol. 2(2), 134–141 (2012).
- Pica N, Hai R, Krammer F et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl Acad. Sci. USA 109(7), 2573–2578 (2012).
- Krammer F, Pica N, Hai R, Margine I, Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87(12), 6542–6550 (2013).
- Margine I, Hai R, Albrecht RA et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J. Virol. 87(8), 4728–4737 (2013).
- Wei CJ, Yassine HM, McTamney PM et al. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci. Transl. Med. 4(147), 147ra114 (2012).
- Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. doi:10.1016/j.coviro.2013.07.007 (2013) ( Epub ahead of print).
- Margine I, Krammer F, Hai R et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza a viruses. J. Virol. doi:10.1128/JVI.01715-13 (2013) ( Epub ahead of print).
- Palese P, Wang TT. Why do influenza virus subtypes die out? A hypothesis. MBio 2(5) (2011).
- Easterbrook JD, Schwartzman LM, Gao J et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432(1), 39–44 (2012).
- Wan H, Gao J, Xu K et al. Molecular Basis for Broad Neuraminidase Immunity: Conserved Epitopes in Seasonal and Pandemic H1N1 as Well as H5N1 Influenza Viruses. J. Virol. 87(16), 9290–9300 (2013).
- Rockman S, Brown LE, Barr IG et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J. Virol. 87(6), 3053–3061 (2013).
- Talaat KR, Karron RA, Callahan KA et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 27(28), 3744–3753 (2009).
- el-Madhun AS, Cox RJ, Soreide A, Olofsson J, Haaheim LR. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J. Infect. Dis. 178(4), 933–939 (1998).
- Wilkinson TM, Li CK, Chui CS et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18(2), 274–280 (2012).
- Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877–3882 (2009).
- Pedersen GK, Madhun AS, Breakwell L et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J. Infect. Dis. 206(2), 158–166 (2012).
- Pathirana RD, Bredholt G, Akselsen PE, Pedersen GK, Cox RJ. A(H1N1)pdm09 vaccination of healthcare workers: improved immune responses in low responders following revaccination. J. Infect. Dis. 206(11), 1660–1669 (2012).
- McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176(10), 6333–6339 (2006).
Website
- H5N1 and H7 LAIV-IAV Prime-Boost Studies. http://www.who.int/vaccine_research/meetings/Kanta_Subbarao.pdf